Media Contact:
Stephen Majors
Senior Director, Public Affairs
smajors@alliancerm.org
Brussels, BE
The legislative revision is an opportunity for EU policymakers to help address the EU’s stagnation in ATMP clinical trials, company formation, and investment in comparison to the US and China. While the 26 April Commission proposal in some ways improves upon an earlier version, it still falls significantly short of building a sustainable future for the ATMP sector and providing access for EU patients.
Washington, DC
Advancing value-based payment arrangements for cell and gene therapy has been a long-standing priority for ARM, and we view this as a step in the right direction to promoting access to cell and gene therapies for the Medicaid patients that need them.
Washington, DC
As the global voice of the cell and gene therapy sector, ARM believes courts lack the technical expertise to second-guess the FDA’s scientific and medical judgment.
Washington, DC
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the engineered cell therapy and genetic medicines sector, announced the appointment of Rita Johnson-Greene as Chief Operating Officer, effective April 10.
